| AR | absolute risk; accounts receivable; achievement ratio; actinic reticuloid [syndrome]; active resista... |
|---|---|
| BLVR | biliverdin reductase |
| CBR | carbonyl reductase; chemical, biological, and radiological [warfare]; chemically-bound residue; chro... |
| DHFR | dihydrofolate reductase |
| DHFRase | dihydrofolate reductase |
| serotonin uptake inhibitors | Compounds that specifically inhibit the reuptake of serotonin in the brain. This increases the serotonin concentration in the synaptic cleft which then activates serotonin receptors to a greater extent. These agents have been used in treatment of depression, panic disorder, obsessive-compulsive behaviour, and alcoholism, as analgesics, and to treat obesity and bulimia. Many of the adrenergic uptake inhibitors also inhibit serotonin uptake; they are not included here. (12 Dec 1998) |
|---|---|
| neurotransmitter uptake inhibitors | Drugs that inhibit the transport of neurotransmitters into axon terminals or into storage vesicles within terminals. For many transmitters, uptake determines the time course of transmitter action so inhibiting uptake prolongs the activity of the transmitter. Blocking uptake may also deplete available transmitter stores. Many clinically important drugs are uptake inhibitors although the indirect reactions of the brain rather than the acute block of uptake itself is often responsible for the therapeutic effects. (12 Dec 1998) |
| nucleic acid synthesis inhibitors | Compounds that inhibit cell production of DNA or RNA. (12 Dec 1998) |
| dopamine uptake inhibitors | Drugs that block the transport of dopamine into axon terminals or into storage vesicles within terminals. most of the adrenergic uptake inhibitors also inhibit dopamine uptake. (12 Dec 1998) |
| integrase inhibitors | Compounds which inhibit or antagonise biosynthesis or actions of integrase. (12 Dec 1998) |
| tissue inhibitors of metalloproteinase | <cell biology> Family of proteins of around 200 residues that can inhibit metalloproteinases, for example collagenase, by binding to them. (18 Nov 1997) |
| enzyme inhibitors | Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (12 Dec 1998) |
| enzymes, coenzymes, and enzyme inhibitors | Proteins or RNA that act as biological catalysts, their cofactors, and inhibitors. (12 Dec 1998) |
| trypsin inhibitors | Serine proteinase inhibitors which inhibit trypsin. They may be endogenous or exogenous compounds. (12 Dec 1998) |
| lipoxygenase inhibitors | Compounds or agents that combine with lipoxygenase and thereby prevent its substrate-enzyme combination with arachidonic acid and the formation of the eicosanoid products hydroxyeicosatetraenoic acid and various leukotrienes. (12 Dec 1998) |
| acetoacetyl-CoA reductase | An oxidoreductase catalyzing interconversion of a 3-oxoacyl-CoA and NADPH, and the corresponding d-3-hydroxyacyl-CoA, and NADP+. A step in fatty acid synthesis. (05 Mar 2000) |
| acetohexamide reductase | <enzyme> Catalyses the conversion of acetohexamide to (-)-hydroxyhexamide Registry number: EC 1.1.1.- (26 Jun 1999) |
| acryloyl-CoA reductase | <enzyme> Clostridium kluyveri enzyme; contains fmn, ferredoxin, and flavodoxin; can act as electron donors Registry number: EC 1.3.99.- Synonym: acryloyo-coenzyme a reductase (26 Jun 1999) |
| aflatoxin B1 aldehyde reductase | <enzyme> Catalyses the conversion of the dialdehydic form of aflatoxin b1-dihydrodiol to the dialcohol form Registry number: EC 1.1.1.- Synonym: aflatoxin b1-aldehyde reductase, afb1-ar (26 Jun 1999) |
| aflatoxin B1 reductase | <enzyme> Reduces the cyclopentenone ring of aflatoxin b1 to aflatoxicol; requires NADPH as cofactor Registry number: EC 1.1.1.- (26 Jun 1999) |